Background. The Assessments of Spondyloarthritis international Society (ASAS) classification criteria for axial spondyloarthritis (axSpA) have been criticized because of insufficient differentiation towards FM. The aim of this study was to compare the performance of currently used classification criteria in patients diagnosed with axSpA or FM.
Introduction
Patients diagnosed with axial spondyloarthritis (axSpA) can be classified as non-radiographic axial spondyloarthritis (nr-axSpA) or radiographic axSpA, which can be used as a synonym for the 'classical' AS [1] . AxSpA is a chronic inflammatory rheumatic disease that affects mainly the axial skeleton but also peripheral joints and entheses, and extraarticular manifestations in the eye, the skin and the gut are known to occur in many patients.
With a prevalence of about 0.5%, axSpA is among the most frequent rheumatic diseases [2] . The pathognomonic findings of axSpA are inflammatory and osteoproliferative changes in the SI joint and the spine [3] . The underlying pathology of these changes is a rheumatic inflammation often starting at entheseal sites, which also affects bony structures [4] . New bone formation in axSpA classically appears in the form of syndesmophytes and ankylosis, which can be visualized on conventional radiographs [5] . There is a strong genetic component in the pathogenesis of axSpA with HLA-B27 as the main marker [6] .
Although the burden of disease has been shown to be largely similar in nr-axSpA and AS [2] , there are two major differences: there is a higher proportion of males in AS and, correspondingly, a higher proportion of females in nraxSpA, which is due to the fact that males develop more bone formation than females [5] , and there is a lower degree of inflammation in nr-axSpA as documented by differences in CRP levels and bone marrow oedema as visualized by MRI [7] . Furthermore, patients with nr-axSpA tend to be somewhat younger than those with established AS [8] . Because of the difficulties in scoring less severe radiographic changes in the SIJ, the cut-off between the two forms has caused difficulties in differentiation [9] . Therefore, it has been suggested that the terms nr-axSpA and AS should not be used for diagnostic purposes-the term axSpA is sufficient [10] .
Clinically, patients with axSpA report chronic back pain starting before the age of 45, which is usually reported as inflammatory back pain, often associated with spinal stiffness [2] . However, patients with axSpA sometimes also report widespread pain and fatigue [11, 12] .
FM is a non-inflammatory chronic musculoskeletal disease that is characterized by chronic widespread pain. Its prevalence is estimated at around 2%. The majority of patients with FM are female [13] . The most characteristic symptoms of FM are widespread pain and fatigue [14, 15] , but patients with FM may also present with chronic back pain, morning stiffness and functional impairment, which may be a challenge for a diagnostic differentiation from axSpA [16, 17] .
New classification criteria for both axSpA and FM have been published [1, 18] . The criteria for axSpA published in 2009 by the Assessments of Spondyloarthritis international Society (ASAS) [1] include both AS and nr-axSpA, thus replacing the ESSG [19] and the Amor et al. [20] criteria and including the 1984 modified New York criteria [21] . The ASAS criteria have chronic back pain as the main symptom, including imaging findings on MRI or radiography and presence of HLA-B27, together with a list of characteristic SpA features.
For FM, diagnostic criteria were published by ACR 2010 [18] , replacing the classification criteria published in 1990 [22] . In 2011, a patient's self-report modification was proposed and very recently, in 2016, another revision was published [23] that combines the 201011 criteria and adds a generalized pain feature in order to minimize misclassification of regional pain disorders and eliminate confusion that may have occurred for diagnosis based on the existing criteria sets.
The ASAS classification criteria have been recently challenged for several reasons [24] , and therefore, the United States Food and Drug Administration (FDA), in contrast to the European Medicines Agency, has refused to approve the use of TNFa inhibitors for patients identified as being at the stage of nr-axSpA. The main concern here probably was the possible overdiagnosis of axSpA with the consequence of erroneous treatment decisions. This is especially important when it comes to treatments with expensive and/or potentially hazardous medications such as biologic compounds, which are currently recommended for treatment of patients with axial SpA directly after failure of NSAIDs [25] . In this context, one of the main questions that have been raised is whether a large percentage of patients with FM will fulfil ASAS classification criteria.
In the present study, we analyse the similarities and differences between patients diagnosed and classified with axSpA and FM using different sets of criteria and various established assessments. The main task of the study was to evaluate whether FM patients may be misclassified as having axSpA when the ASAS criteria are applied.
Methods
Patients were prospectively included into the study either from our specialized hospital's outpatient clinic or in collaborating rheumatology practices based on the diagnosis of the treating rheumatologist. After referral, all patients were examined by an independent expert to check whether the ASAS classification criteria for axSpA [1] and/or the 2010 ACR diagnostic criteria or the classification for FM [18, 22] were fulfilled. The study was conducted from December 2013 to December 2014, directly after the above mentioned discussion by the FDA and European Medicines Agency, which is why the 2016 revision of the FM criteria could not be tested here.
Since patients with FM who report to the clinic usually have high pain levels, a high disease activity as assessed by a BASDAI 54 was also required for axSpA patients for reasons of comparability and simulation of a situation close to the one required for treatment with biologics [25] .
The major exclusion criterion for patients with axSpA was psoriasis because of the relatively high prevalence of enthesitis and widespread pain in PsA [26, 27] . Furthermore, we excluded patients with current or past treatment with biologics, to have a more homogeneous population and in order not to confuse the clinical situation.
Taken together, all patients included in the study had been diagnosed and fulfilled the classification criteria for the respective diseases by rheumatologists.
All relevant current treatments for pain such as NSAIDs and analgesics as well as anti-depressants were recorded. The intake of NSAIDs was quantified by the ASAS-NSAID index [28] . Information on imaging of the SI joints was available in all patients. The HLA-B27 status was known for all axSpA patients, and for all FM patients for whom the information had been available prior to inclusion in the study (see below).
Assessments of the symptom severity and disease activity was based on established instruments for both diseases, which were applied to all patients, independent of their diagnosis. Patient-reported outcomes were obtained using the BASDAI [29] , the Fibromyalgia Impact Questionnaire [30] , the HAQ [31] and a general pain index with a 010 numeric rating scale. The BASFI [32] was collected only in patients with axSpA based on the protocol submitted to and finally approved by the ethical committee. Among the objective assessments obtained were laboratory markers for inflammation, especially the CRP, the ASDAS-CRP [33] and the Maastricht AS enthesitis score (MASES) [34] .
A total of 300 patients were included without any preselection except their respective diagnosis by the managing rheumatologist, aiming for a total of 200 patients with axSpA (100 with AS and 100 with nr-axSpA) and 100 with FM. When each of the groups had reached the planned number of patients, no further patients were recruited for this group. There was no additional bias for patient selection except for the already mentioned exclusion criteria. Overall, in the FM group, we recruited 30 FM patients from cooperating rheumatologists and 70 patients from our hospital's outpatient clinic. For the SpA group, 33 and 29 patients were recruited for AS and nr-axSpA, respectively, from practicing rheumatologists, while 67 and 71 patients for AS and nr-axSpA, respectively, were recruited from patients presenting in our hospital.
In addition, a differentiation based on the time point of diagnosis was made for patients with duration since diagnosis of <6 months (incident disease) and for patients with duration since diagnosis 56 months (prevalent disease).
For statistical analyses, the mean values between groups were compared by the MannWhitney U-test. Binary variables were compared using Fisher's exact test for proportions. A P-value 40.05 was considered statistically significant. Calculations and statistical analysis were performed using SPSS Statistics v23.0 (IBM Corp., Armonk, NY, USA).
The study was approved by the local Ethical Committee (Aerztekammer Westfalen-Lippe, approval number 2013-192-f-S) and informed patient consent was obtained from all patients for this study.
Results

Baseline characteristics and patient distribution to subgroups
The baseline characteristics and demographics and of the patients are shown in Table 1 .
Classification of patients based on different criteria
Among the 100 patients diagnosed as FM based on fulfilment of the 2010 ACR diagnostic criteria, 98 (98%) also fulfilled the 1990 classification ACR criteria for FM. Overall, 40 patients with FM had HLA-B27 information available. Out of those, two patients fulfilled the 2009 ASAS classification criteria for axSpA (5%); both of them were imaging-positive based on the 2009 ASAS criteria (imaging arm; Table 2 ) but were not diagnosed as axSpA by the managing rheumatologist. None of the patients in which no HLA-B27 testing had been performed had more than one clinical feature of axSpA (either a good response to NSAIDs or a slightly elevated CRP) and none had any other feature characteristic for SpA as listed in the ASAS classification criteria. Thus, they could not possibly have fulfilled these criteria.
In comparison, out of 200 patients classified as axSpA, 48 (24%) fulfilled the 2010 ACR diagnostic criteria and 27 (13.5%) fulfilled the 1990 ACR classification criteria for FM. Overall, more patients fulfilling the 2010 ACR diagnostic criteria for FM were classified as nr-axSpA by the imaging arm ( Table 2) . Out of 108 patients with prevalent axSpA, 35 fulfilled the 2010 ACR diagnostic criteria (32.4%) and 17 the 1990 ACR classification criteria for FM (15.7%), while out of 92 patients with incident axSpA, 13 fulfilled the 2010 ACR diagnostic criteria (14.1%) and 11 the 1990 ACR classification criteria for FM (12%). The highest proportion of patients fulfilling FM criteria was found in the group of prevalent AS patients, in contrast to incident patients.
There were no large differences in the SpA group between males and females with respect to fulfilment of the different FM criteria but more AS patients were positive for FM independent of the criteria set used for FM classification or diagnosis. The detailed rates for both criteria and incident and prevalent cases differentiated by gender are shown in Table 3 .
Furthermore, there were no differences between axSpA patients with normal (n = 74) or increased (n = 126) CRP values with respect to the proportion of those fulfilling both FM criteria sets: 20/74 (27.0%) axSpA patients with normal CRP vs 28/126 (22.2%) axSpA patients with increased CRP fulfilled the 2010 ACR diagnostic criteria for FM, and 10/74 (13.5%) axSpA patients with normal CRP vs 18/126 (14.3%) axSpA patients with increased CRP fulfilled the 1990 ACR classification criteria for FM.
Comparison of clinical assessments
Patients with FM showed higher scores in all assessments as compared with axSpA, with the exception of ASDAS. Detailed results for all parameters including comparisons between AS and nr-axSpA are shown in Table 4 .
Discussion
This is the first study to prospectively compare similarities and differences between patients with axSpA and FM using rheumatologists' evaluation and established classification or diagnostic criteria, respectively, in a real-life setting.
The most important result of this study is that patients with newly diagnosed or established FM only very rarely fulfil classification criteria for axSpA. Furthermore and importantly, patients with established AS fulfilled FM criteria more often than patients classified as nr-axSpA. Both results clearly argue against a major flaw of the ASAS classification criteria in relation to misclassification of patients with FM as having axSpA at any stage.
The topic of our study is of special importance also in relation to a debate that started in 2013, after the public hearing of the FDA Arthritis Advisory Committee Meeting, the consequence of which was the refusal for TNF blockers to be approved for the indication of nr-axSpA [24] . So far, no drug is currently approved in the USA for nr-axSpA because of conceptual issues with that classification, one major reason for which is the fear that the ASAS classification criteria have important practical limitations being more inclusive than the modified New York criteria that have radiographic evidence of structural changes in the SI joints as a mandatory criterion. Thus, especially the 'non-radiographic' part of the ASAS classification criteria is believed to possibly lead to overinterpretation and misclassification, which in consequence, may induce overtreatment of patients with chronic back pain and FM, who may just show minor MRI changes such as a small bone marrow oedema in the SIJ or a positive HLA-B27 finding.
Another interesting finding of our study is that 24% of patients with axSpA fulfilled the 2010 ACR diagnostic criteria for FM. Importantly, this was much more often the case in patients with AS (29%) than with nr-axSpA (19%). This, again, provides reassurance that patients classified as nr-axSpA are not especially prone to have FM-like symptoms and rather suggests that widespread pain also occurs in patients with established AS, where a high degree of back pain is found due to the late stage of the disease. The tendency for FM criteria to be more frequently fulfilled in the prevalent patients is also consistent with the observation that widespread pain occurs more often in patients with longstanding disease. Of note, the 1990 ACR classification criteria, despite some similarities with the MASES (see below), were fulfilled by fewer patients with axSpA than the 2010 ACR diagnostic criteria for FM. These numbers are similar to recent data from the DESIR cohort [35] but higher than earlier reports on patients with established AS from the REGISPONSER cohort [36] and lower in comparison with data from other cohorts of patients who primarily presented with inflammatory back pain who were also examined for spinal tender points [37] . In a study performed in specialized back pain clinics [38] , even 42% of patients fulfilled the 1990 ACR classification criteria for FM. Possible differences between these cohorts may be due to the different populations studied.
Another important finding of this study is that we did not observe differences between female and male axSpA patients who fulfilled the FM criteria. This is in contrast to the knowledge that a relatively high degree of FM can be found in women [39, 40] ; however, no study has performed a comparison between genders in the different axSpA stages so far.
FM is the current term for chronic widespread musculoskeletal pain for which no alternative cause can be identified. The underlying mechanisms, in both human and animal studies, for the continued pain in individuals with FM are not entirely clear. There is a substantial amount of support for alterations of central nervous system nociceptive processing in people with FM, and that psychological factors such as stress can enhance the pain experience. However, other potential mechanisms including a peripheral nervous system component to the generation of pain and the role of systemic inflammation are now increasingly being explored [41] . FM is also one of the central sensitivity syndromes that are associated with irritable bowel syndrome, temporomandibular disorder, restless legs syndrome, chronic fatigue syndrome and other similar chronic painful conditions that are based on central sensitization [42] . Indeed, an increased prevalence of FM has been reported in other chronic pain conditions with inflammatory and/or structural pathology such as diabetes mellitus, RA, lupus, OA, IBD and AS [43] . The latter could be clearly confirmed in this study.
Finally, our study also shows that instruments for assessment of disease burden commonly thought of as being disease specific are in fact not. We found that presumptively disease-related indices such as BASDAI and MASES, developed to assess disease activity and entheseal pain of patients with axSpA, showed the highest values in patients with FM. The main reason for these high values is that in patients with FM, widespread pain is the most important symptom and that entheseal pain induced by local pressure, the usual procedure performed when the 1990 ACR criteria for FM are assessed, is close to the tender points of the MASES. Instruments developed specifically for AS such as the spinal pain score [44] have items included that are similar to the FM questionnaire, but these were not used in this study. The presumptively most disease-specific test that performed the best in our study was the ASDAS-CRP, which showed similar values for both groups, irrespective of classification or diagnosis. This was different in another database containing patients with AS and axial PsA [45, 46] , possibly due to the inclusion of axial PsA patients, who may present clinically differently. The main message deriving from these data is that such indices should not be misused as diagnostic tools for axSpA and they are not appropriate for use in FM.
A potential weakness of our study may be that, for practical reasons, not all FM patients included in the study had HLA-B27 test results available. This may have led to underestimation of the proportion of FM patients fulfilling the ASAS classification criteria. However, on the assumption that the overall prevalence of HLA-B27 is about 8%, which it is known to be in Germany [2] -which would apply in a similar way to patients with FM and that 5% of such individuals could indeed have axSpA [6] -the results would not have been much different. Furthermore, we were not able to use the 2016 revision of the FM criteria since these were not available at the time of the conduction of the study. Nevertheless, since the main task of this study was to evaluate whether FM patients may be misclassified as having axSpA when the ASAS criteria are applied and not the other way around, we do not think that this represents a major issue for the results presented here.
In conclusion, in this prospective study, we found that very few patients with the diagnosis of FM fulfilled the ASAS classification criteria, while some axSpA patients fulfilled the 2010 ACR diagnostic criteria for FM. The ASAS classification criteria proved to be functioning well also for the differentiation of FM. On the other hand, some patients with widespread pain may have underlying axSpA. This differential diagnosis needs to be considered when dealing with a diagnosis of FM in daily practice. Furthermore, activity measures do not differentiate between patients with axSpA and FM, including the enthesitis and back pain measure MASES.
Future studies will need to assess the possible treatment effect of NSAIDs and biologics in patients with axSpA who fulfil FM criteria as compared with those who don't. Since it is often a difficult clinical task to treat widespread FM-related pain, it is, finally, important to stress the challenge of diagnosis and management of FM in underlying rheumatic diseases since these are of crucial importance to, for example, avoid unwarranted use of immunosuppressant medication [43] .
